StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
24
Publishing Date
2023 - 11 - 21
1
2023 - 10 - 24
1
2023 - 10 - 02
1
2023 - 04 - 27
1
2023 - 02 - 06
1
2023 - 01 - 06
1
2022 - 08 - 11
1
2022 - 06 - 28
1
2022 - 06 - 02
1
2022 - 04 - 26
1
2022 - 03 - 29
1
2022 - 01 - 24
1
2022 - 01 - 10
1
2021 - 12 - 24
1
2021 - 12 - 13
1
2021 - 08 - 13
1
2021 - 08 - 03
1
2021 - 06 - 23
1
2021 - 06 - 10
2
2021 - 05 - 14
1
2021 - 05 - 07
1
2021 - 05 - 05
1
2021 - 03 - 11
1
Sector
Commercial services
3
Distribution services
1
Finance
3
Health technology
24
Technology services
1
Transportation
1
Tags
Agreement
25
Alliances
39
Alzheimer's
23
Alzheimer’s
23
Antibody
51
Approval
46
Biomidwest
40
Biopharma
36
Biotech-bay
24
Biotechnology
25
Cancer
139
China
47
Chinese
28
Clinical-trials-phase-iii
32
Collaboration
71
Companies
51
Conference
76
Covid
62
Covid-19
48
Designation
22
Diabetes
57
Disease
89
Drug
105
Earnings
45
Events
32
Expected
24
Fda
71
Financial
65
Financial results
42
Global
149
Growth
108
Health
30
Heart
23
Insulin
37
Iot
23
License
26
Market
305
Meeting
26
Money
34
N/a
1119
Obesity
28
People
70
Pharma
35
Pharmaceutical
24
Phase 1
24
Phase 2
34
Phase 3
47
Positive
30
Report
140
Research
148
Results
203
Risk
24
Study
74
Technology
27
Therapeutics
138
Therapy
88
Tirzepatide
24
Treatment
175
Trial
116
Update
33
Entities
10x genomics, inc.
13
Abvc biopharma inc
12
Accuray incorporated
13
Adicet bio, inc.
16
Agilent technologies, inc.
34
Aligos therapeutics, inc.
16
Amgen inc.
28
Anixa biosciences, inc.
21
Arcus biosciences, inc.
15
Aslan pharmaceuticals limited
12
Atara biotherapeutics, inc.
24
Avinger, inc.
14
Beigene, ltd.
15
Better therapeutics inc
19
Bio-rad laboratories, inc.
21
Biocardia, inc.
12
Biomea fusion inc
12
Biotelemetry, inc.
14
Biotricity inc
18
Bridgebio pharma, inc.
15
Bristol-myers squibb company
15
Caredx, inc.
27
Coherus biosciences, inc.
13
Cymabay therapeutics inc.
16
Cytomx therapeutics, inc.
13
Durect corporation
12
Dynavax technologies corporation
19
Eiger biopharmaceuticals, inc.
20
Eli lilly and company
24
Exelixis, inc.
24
Geron corporation
23
Gilead sciences, inc.
48
Guardant health, inc.
37
Humanigen, inc.
13
Ideaya biosciences, inc.
24
Jaguar health, inc.
22
Johnson & johnson
28
Mirum pharmaceuticals, inc.
49
Morgan stanley
27
Nanostring technologies, inc.
15
Nektar therapeutics
16
Nevro corp.
17
Novabay pharmaceuticals, inc.
24
Nurix therapeutics, inc.
15
Outset medical, inc.
21
Personalis, inc.
26
Pulse biosciences, inc
31
Renovorx inc
14
Rigel pharmaceuticals, inc.
13
Sangamo therapeutics, inc.
20
Sanofi
43
Summit therapeutics inc.
13
Sutro biopharma, inc.
16
Twist bioscience corporation
53
Ultragenyx pharmaceutical inc.
16
Vaxart, inc.
16
Vaxcyte, inc.
15
Veracyte, inc.
51
Vir biotechnology, inc.
16
Vistagen therapeutics, inc.
29
Symbols
ABT
1
ALXO
3
AMGN
2
ARE
1
ARQT
1
BGNE
1
CSX
1
GILD
1
GSK
1
INCY
4
LLY
24
MCK
1
MET
1
MTCR
1
NKTR
2
PCVX
1
REGN
1
RIGL
4
SANA
1
SNY
4
SNYNF
3
VIR
1
WDAY
1
WFC
1
XNCR
1
Exchanges
Nasdaq
20
Nyse
24
Crawled Date
2023 - 11 - 21
1
2023 - 10 - 24
1
2023 - 10 - 02
1
2023 - 04 - 27
1
2023 - 02 - 06
1
2023 - 01 - 06
1
2022 - 08 - 11
1
2022 - 06 - 29
1
2022 - 06 - 02
1
2022 - 04 - 26
1
2022 - 03 - 30
1
2022 - 01 - 24
1
2022 - 01 - 10
1
2021 - 12 - 24
1
2021 - 12 - 13
1
2021 - 08 - 13
1
2021 - 08 - 03
1
2021 - 06 - 23
1
2021 - 06 - 10
2
2021 - 05 - 14
1
2021 - 05 - 07
1
2021 - 05 - 05
1
2021 - 03 - 11
1
Crawled Time
01:00
2
09:00
1
12:00
4
12:15
2
12:30
1
13:01
1
13:20
1
14:00
5
14:30
1
15:00
1
16:00
2
17:00
1
18:00
1
23:00
1
Source
www.biospace.com
24
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Biotech-bay
entities :
Eli lilly and company
save search
Alto Neuroscience Closes $45 Million in Oversubscribed Series C Financing
Published:
2023-11-21
(Crawled : 18:00)
- biospace.com/
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
25.63%
|
O:
0.07%
H:
0.0%
C:
0.0%
series
Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia
Published:
2023-10-24
(Crawled : 14:00)
- biospace.com/
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
28.15%
|
O:
-0.84%
H:
0.0%
C:
0.0%
SNY
|
News
|
$45.39
-1.56%
-1.58%
4.3M
|
Health Technology
|
-12.46%
|
O:
0.77%
H:
0.0%
C:
0.0%
thn391
treatment
dementia
trial
potential
results
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
Published:
2023-10-02
(Crawled : 14:00)
- biospace.com/
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
37.58%
|
O:
-1.77%
H:
0.0%
C:
0.0%
NKTR
|
$1.32
-2.22%
-3.85%
2.4M
|
Health Technology
|
126.66%
|
O:
-2.01%
H:
4.52%
C:
-2.35%
t-cell
congress
therapeutics
therapy
Therini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases
Published:
2023-04-27
(Crawled : 14:00)
- biospace.com/
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
99.53%
|
O:
3.98%
H:
1.86%
C:
-0.23%
SNY
|
News
|
$45.39
-1.56%
-1.58%
4.3M
|
Health Technology
|
-21.24%
|
O:
-3.56%
H:
0.0%
C:
0.0%
neurodegenerative
IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy
Published:
2023-02-06
(Crawled : 15:00)
- biospace.com/
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
121.41%
|
O:
0.86%
H:
0.42%
C:
-1.26%
ARE
A
|
$116.51
0.05%
0.36%
1.1M
|
Finance
|
-30.28%
|
O:
-1.29%
H:
1.54%
C:
0.98%
antibody
peanut
program
Innovent Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the NDA for Parsaclisib (PI3Kδ inhibitor) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published:
2023-01-06
(Crawled : 09:00)
- biospace.com/
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-6.17%
|
O:
-0.35%
H:
0.0%
C:
-2.69%
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
109.17%
|
O:
0.3%
H:
1.86%
C:
0.82%
SNY
|
News
|
$45.39
-1.56%
-1.58%
4.3M
|
Health Technology
|
-4.67%
|
O:
0.02%
H:
0.0%
C:
0.0%
INCY
|
$52.82
0.19%
0.19%
1.5M
|
Health Technology
|
-34.11%
|
O:
1.05%
H:
0.2%
C:
-0.16%
treatment
designation
medical
granted
review
china
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer
Published:
2022-08-11
(Crawled : 16:00)
- biospace.com/
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
146.47%
|
O:
-1.18%
H:
1.46%
C:
0.05%
ALXO
M
|
$15.74
-2.11%
-2.29%
670K
|
Commercial Services
|
13.29%
|
O:
2.97%
H:
6.15%
C:
-1.44%
trial
cancer
phase 2
Innovent Announces Phase 1b Study Results of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Published in Nature Communications
Published:
2022-06-28
(Crawled : 01:00)
- biospace.com/
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
132.0%
|
O:
0.99%
H:
0.0%
C:
0.0%
INCY
|
$52.82
0.19%
0.19%
1.5M
|
Health Technology
|
-31.72%
|
O:
-0.08%
H:
0.0%
C:
0.0%
ibi362
communications
chinese
diabetes
results
phase 2b
IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published:
2022-06-02
(Crawled : 17:00)
- biospace.com/
SANA
|
$7.73
-6.42%
-6.72%
1.9M
|
|
55.12%
|
O:
-6.1%
H:
9.2%
C:
8.6%
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
139.99%
|
O:
-0.9%
H:
0.0%
C:
0.0%
INCY
|
$52.82
0.19%
0.19%
1.5M
|
Health Technology
|
-29.55%
|
O:
-0.4%
H:
0.25%
C:
-0.07%
treatment
drug
application
Rigel Announces Conference Call and Webcast to Report First Quarter 2022 Financial Results and Business Update
Published:
2022-04-26
(Crawled : 13:20)
- biospace.com/
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
163.24%
|
O:
0.34%
H:
1.41%
C:
-1.17%
RIGL
|
$1.05
-5.41%
-4.72%
1.2M
|
Health Technology
|
-60.38%
|
O:
-0.38%
H:
4.92%
C:
-4.55%
conference
report
results
Innovent Announced 2021 Annual Results
Published:
2022-03-29
(Crawled : 01:00)
- biospace.com/
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
157.41%
|
O:
0.13%
H:
0.38%
C:
-1.25%
results
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma
Published:
2022-01-24
(Crawled : 12:30)
- biospace.com/
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
203.43%
|
O:
-1.97%
H:
0.5%
C:
-0.88%
pemazyre
treatment
ema
ces
approval
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022
Published:
2022-01-10
(Crawled : 12:00)
- biospace.com/
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
188.94%
|
O:
-0.5%
H:
0.0%
C:
0.0%
ALXO
M
|
$15.74
-2.11%
-2.29%
670K
|
Commercial Services
|
-25.69%
|
O:
-0.46%
H:
2.63%
C:
1.7%
milestone
Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT®
Published:
2021-12-24
(Crawled : 14:00)
- biospace.com/
INCY
|
$52.82
0.19%
0.19%
1.5M
|
Health Technology
|
Email alert
Add to watchlist
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
Email alert
Add to watchlist
tyvyt
new drug
application
drug
china
Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual Meeting
Published:
2021-12-13
(Crawled : 14:30)
- biospace.com/
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
209.43%
|
O:
1.27%
H:
0.0%
C:
0.0%
NKTR
|
$1.32
-2.22%
-3.85%
2.4M
|
Health Technology
|
-89.29%
|
O:
-3.33%
H:
0.0%
C:
0.0%
nktr-255
ema
car-t
therapeutics
therapy
Rigel Pharmaceuticals Provides Update on COVID-19 Program
Published:
2021-08-13
(Crawled : 12:15)
- biospace.com/
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
184.95%
|
O:
0.2%
H:
0.0%
C:
0.0%
RIGL
|
$1.05
-5.41%
-4.72%
1.2M
|
Health Technology
|
-74.58%
|
O:
-16.22%
H:
0.0%
C:
0.0%
covid
covid-19
program
Amgen Reports Second Quarter 2021 Financial Results
Published:
2021-08-03
(Crawled : 23:00)
- biospace.com/
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
204.45%
|
O:
-0.75%
H:
5.97%
C:
4.59%
XNCR
|
$18.95
-0.63%
-0.47%
470K
|
Health Technology
|
-38.22%
|
O:
0.55%
H:
1.32%
C:
1.03%
REGN
|
$893.99
-0.8%
-0.84%
450K
|
Health Technology
|
56.15%
|
O:
-0.05%
H:
1.86%
C:
1.67%
BGNE
|
$131.96
0.08%
0.06%
110K
|
Health Technology
|
-59.06%
|
O:
0.21%
H:
4.53%
C:
4.06%
AMGN
|
$262.75
-0.5%
-0.49%
1.4M
|
Health Technology
|
10.49%
|
O:
0.4%
H:
1.51%
C:
1.38%
financial results
results
report
Amunix Appoints Industry Veteran, Frank Watanabe, to its Board of Directors
Published:
2021-06-23
(Crawled : 12:00)
- biospace.com/
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
239.04%
|
O:
0.34%
H:
0.02%
C:
-2.29%
ARQT
A
|
$9.45
-7.81%
-8.47%
2.5M
|
Health Technology
|
-61.74%
|
O:
-0.27%
H:
2.83%
C:
2.09%
GenapSys™ Appoints Three New Members to its Board of Directors
Published:
2021-06-10
(Crawled : 12:00)
- biospace.com/
MET
|
$69.95
1.49%
0.0%
2.8M
|
Finance
|
6.56%
|
O:
1.39%
H:
0.26%
C:
-2.58%
MCK
|
$518.81
-1.35%
0.22%
630K
|
Distribution Services
|
176.0%
|
O:
0.44%
H:
2.41%
C:
2.15%
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
232.2%
|
O:
0.43%
H:
3.91%
C:
2.89%
WDAY
S
|
$255.64
-0.54%
-0.54%
1.1M
|
Technology Services
|
14.0%
|
O:
-0.08%
H:
1.92%
C:
1.68%
CSX
|
$34.39
0.67%
0.67%
21M
|
Transportation
|
-64.38%
|
O:
0.22%
H:
0.34%
C:
-1.4%
AMGN
|
$262.75
-0.5%
-0.49%
1.4M
|
Health Technology
|
10.61%
|
O:
0.02%
H:
2.4%
C:
2.12%
ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer
Published:
2021-06-10
(Crawled : 12:00)
- biospace.com/
LLY
|
$745.95
-0.64%
-0.81%
1.3M
|
Health Technology
|
232.2%
|
O:
0.43%
H:
3.91%
C:
2.89%
ALXO
M
|
$15.74
-2.11%
-2.29%
670K
|
Commercial Services
|
-75.82%
|
O:
-0.43%
H:
3.82%
C:
2.26%
cancer
agx148
← Previous
1
2
Next →
Gainers vs Losers
60%
40%
Top 10 Gainers
AGBA
|
News
|
$1.03
157.5%
57.94%
120M
|
Finance
ZCMD
|
$1.45
5.84%
52.1%
2.3M
|
Commercial Services
INVO
|
$1.52
100.0%
51.13%
5M
|
Health Technology
ISPC
|
$0.421
97.65%
49.53%
37M
|
Professional, Scientific, and T...
WLGS
|
News
|
$0.5
45.65%
470K
|
OST
|
$0.509
23.81%
45.26%
90K
|
GDHG
|
$0.263
21.76%
40.66%
3.1M
|
XPON
|
News
|
$3.15
63.21%
37.74%
16M
|
TIRX
|
$0.8
65.02%
30.74%
58M
|
BNTC
|
News
|
$6.82
42.08%
30.64%
3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.